Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections. It is an angiotensin II receptor type 2 agonist. The drug was discovered and developed by Professor Anders Hallberg and colleagues at the University of Uppsala.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.